157 related articles for article (PubMed ID: 20084384)
21. [Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].
Junker K; Sanjmyatav J; Heinze C; Walter M; Heinzelmann J; Wunderlich H; Schubert J; Steiner T
Urologe A; 2008 Sep; 47(9):1187-9. PubMed ID: 18688592
[TBL] [Abstract][Full Text] [Related]
22. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
23. RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs.
Beuselinck B; Jean-Baptiste J; Couchy G; Job S; De Reynies A; Wolter P; Théodore C; Gravis G; Rousseau B; Albiges L; Joniau S; Verkarre V; Lerut E; Patard JJ; Schöffski P; Méjean A; Elaidi R; Oudard S; Zucman-Rossi J
Br J Cancer; 2015 Nov; 113(9):1313-22. PubMed ID: 26528707
[TBL] [Abstract][Full Text] [Related]
24. Lord of the rings: a promising novel treatment for renal cell carcinoma?
Johansson M
Eur Urol; 2011 May; 59(5):745-6. PubMed ID: 21276657
[No Abstract] [Full Text] [Related]
25. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
26. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
27. Metastatic renal cell carcinoma: recent advances and current therapeutic options.
Schrader AJ; Hofmann R
Anticancer Drugs; 2008 Mar; 19(3):235-45. PubMed ID: 18510169
[TBL] [Abstract][Full Text] [Related]
28. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
29. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
30. Molecular biology of renal cell carcinoma.
Mellado B; Gascón P
Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
[TBL] [Abstract][Full Text] [Related]
31. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
Rexer H; Steiner T; Grünwald V
Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
[No Abstract] [Full Text] [Related]
32. Treatment of Checkpoint Inhibitor-Induced Vitiligo in a Patient With Metastatic Renal Cell Cancer.
Karri PV; Tahseen D; Patel AB
Dermatitis; 2021 Jul-Aug 01; 32(4):e68-e69. PubMed ID: 33273227
[No Abstract] [Full Text] [Related]
33. New challenges in kidney cancer therapy: sunitinib.
Izzedine H; Billemont B; Thibault F; Rixe O
Ann Oncol; 2007 Jul; 18 Suppl 9():ix83-6. PubMed ID: 17631600
[No Abstract] [Full Text] [Related]
34. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
Albiges L; Escudier B
Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
[TBL] [Abstract][Full Text] [Related]
35. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
37. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
38. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
[No Abstract] [Full Text] [Related]
39. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
40. [Molecular tumor board-renal cell carcinoma].
Grünwald V; Doehn C; Goebell PJ
Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
